Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 13.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | et forth by specific reference in such filing. Item 5.02. Departure of Directors or Principal Officers; Election of Di |
| 17.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 20.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☒ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 10.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. x Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment o |
| 29.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangemen |
| 17.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangemen |
| 16.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangemen |
| 24.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Office |
Stammdaten
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Unternehmen & Branche
| Name | Applied Therapeutics, Inc. |
|---|---|
| Ticker | APLT |
| CIK | 0001697532 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 14,9 Mio. USD |
| Beta | 2,08 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-09-30 | 10-Q | 1,000,000 | -18,990,000 | -0.13 | 34,374,000 | -561,000 |
| 2025-06-30 | 10-Q | 0 | -21,330,000 | -0.15 | 37,342,000 | 17,438,000 |
| 2025-03-31 | 10-Q | 0 | -21,825,000 | -0.15 | 56,907,000 | 36,668,000 |
| 2024-12-31 | 10-K | 455,000 | -105,624,000 | -0.76 | 86,691,000 | 57,006,000 |
| 2024-09-30 | 10-Q | 122,000 | -68,591,000 | -0.48 | 106,566,000 | 5,892,000 |
| 2024-06-30 | 10-Q | 144,000 | 2,898,000 | -0.13 | 127,778,000 | 72,392,000 |
| 2024-03-31 | 10-Q | 190,000 | -83,938,000 | -0.67 | 151,234,000 | 67,294,000 |
| 2023-12-31 | 10-K | 9,993,000 | -119,763,000 | -1.42 | 54,833,000 | -17,146,000 |
| 2023-09-30 | 10-Q | 10,660,000 | -42,370,000 | -0.47 | 45,195,000 | -11,044,000 |
| 2023-06-30 | 10-Q | 10,660,000 | -29,577,000 | -0.37 | 43,646,000 | -4,334,000 |
| 2023-03-31 | 10-Q | 10,660,000 | -10,137,000 | -0.18 | 30,004,000 | -4,072,000 |
| 2022-12-31 | 10-K | -82,508,000 | -2.18 | 38,363,000 | 4,061,000 | |
| 2022-09-30 | 10-Q | -19,101,000 | -0.40 | 56,679,000 | 9,629,000 | |
| 2022-06-30 | 10-Q | -25,857,000 | -0.96 | 78,178,000 | 25,808,000 | |
| 2022-03-31 | 10-Q | -23,121,000 | -0.88 | 64,953,000 | 41,963,000 | |
| 2021-12-31 | 10-K | -105,584,000 | -4.12 | 89,892,000 | 62,539,000 | |
| 2021-09-30 | 10-Q | -28,418,000 | -1.09 | 118,547,000 | 86,701,000 | |
| 2021-06-30 | 10-Q | -25,828,000 | -0.99 | 136,959,000 | 112,440,000 | |
| 2021-03-31 | 10-Q | -24,179,000 | -1.00 | 156,219,000 | 135,221,000 | |
| 2020-12-31 | 10-K | -93,961,000 | -4.28 | 104,506,000 | 81,939,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-16 | Kanter Stacy J. | Director | Open Market Sale | -43,000 | 0.11 | -4,816.00 | -100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.